An implantable device for localized drug delivery and sensing

[摘要] (cont.) The MRSw aggregate in the presence of the analyte they were designed to detect and this aggregation causes a decrease in the transverse relaxation time (T2), which can be detected with magnetic resonance imaging (MRI) or nuclear magnetic resonance relaxometry. In vitro sensing experiments were used to optimize the device design and characterize its performance. In vivo device-based sensing of hCG, a soluble biomarker that is elevated in testicular and ovarian cancer, has been demonstrated. Cell lines secreting hCG were used to produce ectopic tumors in nude mice. The sensing device was implanted and magnetic resonance imaging (MRI) quantified a T2 decrease in mice with tumors compared to control mice (no tumors). This device may be the first continuous monitoring device for cancer that can be implanted at the tumor site and demonstrates feasibility of MRSw measurements in vivo.

[发布机构] Massachusetts Institute of Technology